Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: a population-based study in Taiwan, 2010–2015

BACKGROUND: The standard frontline therapy for patients with diffuse large B cell lymphoma (DLBCL) is R-CHOP. However, patients older than 80 years are excluded from clinical trials. The importance of rituximab and anthracycline remains unknown in extremely elderly DLBCL patients. Here, we incorpora...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Huai-Hsuan, Ko, Bor-Sheng, Chen, Ho-Min, Chen, Li-Ju, Wang, Chen-Yu, Hsiao, Fei-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285734/
https://www.ncbi.nlm.nih.gov/pubmed/32536955
http://dx.doi.org/10.1186/s12979-020-00188-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285734/
https://www.ncbi.nlm.nih.gov/pubmed/32536955
http://dx.doi.org/10.1186/s12979-020-00188-8

Ejemplares similares